Researchers at Propanc Biopharma have announced promising results for their treatment candidate, PRP, which targets pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form of cancer. In preclinical studies, PRP demonstrated over 90% tumor growth inhibition and significantly improved survival rates in animal models. This treatment not only reduced the size of tumors but also showed potential to make chemotherapy more effective by enhancing the sensitivity of resistant cancer cells to standard treatments.

This discovery is particularly relevant for people concerned about cancer, especially those facing the challenges of pancreatic cancer, which has a low five-year survival rate of around 13%. The results suggest that PRP could offer a new avenue for treatment, potentially improving muscle strength and overall health outcomes for patients battling this difficult disease. With the ability to extend survival by more than 2.5 times compared to controls, PRP may represent a significant advancement in cancer care.

Currently, the research is in the early stages, with these findings coming from preclinical models rather than large human trials. While the data is encouraging, it is important to note that further clinical studies are necessary to confirm these benefits in humans. Propanc plans to accelerate its Phase 1b clinical trial, focusing on advanced solid tumors, including pancreatic cancer, and aims to submit the necessary applications soon.

For those interested in the latest cancer treatments, keeping an eye on the progress of PRP could be worthwhile. As research continues, this innovative approach may lead to new options that improve the quality of life and survival for individuals facing pancreatic cancer.

Source: Propanc Biopharma’s announcement on preclinical data